Passage BIO, Inc. (PASG): Total Liabilities
$43.53M
As of 2025-12-31
$20.72M
As of 2026-06-30
+1.1%
3-year compound annual growth
+13.3%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $43.53M | +5.8% | 2026-03-03, Balance as of period end |
| 2024-12-31 | $41.15M | +4.8% | 2026-03-03, Balance as of period end |
| 2023-12-31 | $39.26M | -6.9% | 2025-03-04, Balance as of period end |
| 2022-12-31 | $42.18M | +15.8% | 2024-03-04, Balance as of period end |
| 2021-12-31 | $36.42M | +56.4% | 2023-03-06, Balance as of period end |
| 2020-12-31 | $23.29M | +446.7% | 2022-03-03, Balance as of period end |
| 2019-12-31 | $4.26M | n/a | 2021-03-03, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Passage BIO, Inc. (PASG) | 2025-12-31 | $43.53M | +5.8% |
| Elutia Inc. (ELUT) | 2025-12-31 | $34.68M | -57.9% |
| Cardiff Oncology, Inc. (CRDF) | 2025-12-31 | $16.50M | +15.8% |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | $74.01M | -6.2% |
| Fennec Pharmaceuticals Inc. (FENC) | 2025-12-31 | $35.08M | -31.0% |
| Senti Biosciences Holdings, Inc. (SNTI) | 2025-12-31 | $45.63M | -3.1% |
| Armata Pharmaceuticals, Inc. (ARMP) | 2025-12-31 | $295.48M | +119.8% |
| Alpha Cognition Inc. (ACOG) | 2025-12-31 | $17.20M | +47.7% |
| Cognition Therapeutics Inc (CGTX) | 2025-12-31 | $14.12M | +22.9% |
Compare PASG, ELUT, CRDF, SGMOQ side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗